Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

Core Viewpoint - Mereo BioPharma Group plc reported financial results for the year ended December 31, 2025, highlighting ongoing studies of setrusumab for osteogenesis imperfecta and a financial runway into mid-2027 with $41.0 million in cash [1][10]. Financial Performance - Total research and development expenses decreased by $3.2 million from $20.9 million in 2024 to $17.8 million in 2025, primarily due to reductions in expenses for alvelestat and etigilimab [7]. - General and administrative expenses decreased by $3.4 million from $26.4 million in 2024 to $23.0 million in 2025, attributed to lower accruals for bonuses and reduced professional fees [8]. - The net loss for the full year ended December 31, 2025, was $41.9 million, compared to $43.3 million in 2024, reflecting an operating loss of $40.1 million and a foreign currency translation loss of $6.3 million [9]. - As of December 31, 2025, the company had cash and cash equivalents of $41.0 million, down from $69.8 million in 2024, expected to fund operations into mid-2027 [10]. Product Development and Regulatory Updates - Setrusumab has shown statistically significant improvements in bone mineral density and reductions in vertebral fractures, although it did not achieve statistical significance against primary endpoints in the Phase 3 studies [5]. - The company is in discussions with regulatory agencies regarding the ongoing analyses of data from the Phase 3 Orbit and Cosmic studies of setrusumab [2]. - Mereo anticipates a single Phase 3 trial for alvelestat, enrolling approximately 220 patients, to support regulatory submissions in the U.S. and Europe [5]. - The company has retained EU and UK commercial rights for setrusumab and is in active discussions for the Phase 3 development and commercialization of alvelestat [14]. Shareholder Information - Total ordinary shares issued as of December 31, 2025, were 795,658,504, with total ADS equivalents of 159,131,700 [11]. - The accumulated deficit as of December 31, 2025, was $501.0 million, compared to $462.9 million in 2024 [19].